bromohydrin pyrophosphate profile

bromohydrin pyrophosphate: stimulates human gammadelta T cells; structure in first osurce [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bromohydrin pyrophosphate : An alkyl diphosphate having bromohydrin as the alkyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	3477612
CHEMBL ID	143948
CHEBI ID	340673
SCHEMBL ID	2037203
MeSH ID	M0391953

Synonym
CHEMBL143948
(4-bromo-3-hydroxy-3-methylbutyl) phosphono hydrogen phosphate
brhpp
bromohydrin pyrophosphate
4-bromo-3-hydroxy-3-methylbutyl trihydrogen diphosphate
chebi:340673 ,
303102-05-8
evy1jzz5ke ,
phosphostim
diphosphoric acid, mono(4-bromo-3-hydroxy-3-methylbutyl) ester
unii-evy1jzz5ke
EPITOPE ID:190605
SCHEMBL2037203
iph 1101
iph1101
(r,s)-3-(bromomethyl)-3-butanol-1-yl-disphosphate
mono(4-bromo-3-hydroxy-3-methylbutyl) diphosphate
iph-1101
Q27225730

Role	Description
phosphoantigen	Any antigen that is a phosphorylated microbial metabolite which activates an immune response in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
alkyl diphosphate
organobromine compound	A compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID317317	Agonist activity at human Vgamma9Vdelta2 receptor expressed in T cells assessed as stimulation of TNFalpha release by ELISA	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate.
AID221770	Effective concentration to activate gammadelta T cells	2002	Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22	Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens.
AID216549	Effective concentration range of compound was determined in stimulating Vgamma9 / Vdelta2 T cell	2003	Bioorganic & medicinal chemistry letters, Apr-07, Volume: 13, Issue:7	Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (66.67)	29.6817
2010's	8 (26.67)	24.3611
2020's	2 (6.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.23%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	30 (96.77%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
2,3-diphosphoglycerate 2,3-Diphosphoglycerate: A highly anionic organic phosphate which is present in human red blood cells at about the same molar ratio as hemoglobin. It binds to deoxyhemoglobin but not the oxygenated form, therefore diminishing the oxygen affinity of hemoglobin. This is essential in enabling hemoglobin to unload oxygen in tissue capillaries. It is also an intermediate in the conversion of 3-phosphoglycerate to 2-phosphoglycerate by phosphoglycerate mutase (EC 5.4.2.1). (From Stryer Biochemistry, 4th ed, p160; Enzyme Nomenclature, 1992, p508). 2,3-bisphosphoglyceric acid : A bisphosphoglyceric acid that is glyceric acid carrying two phospho substituents at positions 2 and 3.	2.42	2	0	bisphosphoglyceric acid; tetronic acid derivative	human metabolite
phosphoglycolate phosphoglycolate: RN given refers to parent acid. 2-phosphoglycolic acid : The O-phospho derivative of glycolic acid.	2.01	1	0	carboxyalkyl phosphate	Escherichia coli metabolite; mouse metabolite
3,3-dimethylallyl pyrophosphate 3,3-dimethylallyl pyrophosphate: isomeric with isopentenyl pyrophosphate. prenyl diphosphate : A prenol phosphate that is a phosphoantigen comprising the O-pyrophosphate of prenol.	2.01	1	0	prenol phosphate	epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
alpha-glycerophosphoric acid [no description available]	2.01	1	0	glycerol monophosphate	algal metabolite; human metabolite
isopentenyl pyrophosphate isopentenyl pyrophosphate: substrate for isopentenyl pyrophosphate isomerase; RN given refers to unlabeled cpd; a nonpeptide mycobacterial antigen that stimulates gamma delta T cells. isopentenyl diphosphate : A prenol phosphate comprising 3-methylbut-3-en-1-ol having an O-diphosphate substituent.	3.27	6	0	prenol phosphate	antigen; antioxidant; epitope; Escherichia coli metabolite; mouse metabolite; phosphoantigen
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	2.01	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.01	1	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
pamidronate [no description available]	2.71	3	0	phosphonoacetic acid
tetraethyl pyrophosphate tetraethyl pyrophosphate: topical agent for glaucoma; structure	2.01	1	0	organic diphosphate
methylphosphate methylphosphate: specifically and irreversibly inactivates inorganic pyrophosphatase; RN given refers to parent cpd. methyl dihydrogen phosphate : A monoalkyl phosphate having methyl as the alkyl group.	2.01	1	0	monoalkyl phosphate; one-carbon compound	algal metabolite; epitope; phosphoantigen
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.01	1	0	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	2.01	1	0
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	3.22	5	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
3-methyl-3,4-epoxybutyl diphosphate 3-methyl-3,4-epoxybutyl diphosphate: structure given in first source; RN given refers to (1-14C)-isomer	2.02	1	0
resiquimod S 28463: structure given in first source	2.25	1	0	imidazoquinoline
ribose 1-phosphate ribose 1-phosphate: RN given refers to (D)-isomer. alpha-D-ribose 1-phosphate : The 1-phospho derivative of alpha-D-ribose.	2.01	1	0	D-ribose 1-phosphate	Escherichia coli metabolite
2-phospholactic acid 2-phospholactic acid: RN given refers to cpd without isomeric designation. 2-phospholactic acid : The phosphoric acid monoester resulting from formal condensation of the alcohol group of lactic acid with phosphoric acid.	2.01	1	0	carboxyalkyl phosphate
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	6.07	27	1	diphosphate ion
(e)-4-hydroxy-3-methylbut-2-enyl diphosphate (E)-4-hydroxy-3-methylbut-2-enyl diphosphate: structure in first source. (2E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate : A prenol phosphate comprising (2E)-4-hydroxy-3-methylbut-2-en-1-ol having an O-diphosphate substituent.	2.71	3	0	prenol phosphate	epitope; Escherichia coli metabolite; phosphoantigen
brefeldin a [no description available]	2.01	1	0	macrolide antibiotic	Penicillium metabolite
alendronate sodium [no description available]	2.01	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.25	1	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.05	1	0

Condition	Relationship Strength	Studies	Trials
Germinoblastoma [description not available]	2.15	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.15	1	0
Epithelial Ovarian Cancer [description not available]	2.08	1	0
Epithelial Neoplasms [description not available]	2.08	1	0
Cancer of Ovary [description not available]	2.08	1	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	2.08	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.08	1	0
Benign Neoplasms [description not available]	4.37	4	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.37	4	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.05	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.05	1	0
Adenocarcinoma, Basal Cell [description not available]	2.05	1	0
Hepatocellular Carcinoma [description not available]	2.05	1	0
Cancer of Liver [description not available]	2.05	1	0
Colorectal Cancer [description not available]	2.05	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.05	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.05	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.05	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.05	1	0
Brill-Symmers Disease [description not available]	2.06	1	0
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	2.06	1	0
Adenocarcinoma Of Kidney [description not available]	2.44	2	0
Cancer of Kidney [description not available]	2.44	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.44	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.44	2	0
Koch's Disease [description not available]	2.02	1	0
HIV Coinfection [description not available]	2.02	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	2.02	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.02	1	0
Pulmonary Consumption [description not available]	2.03	1	0
Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung.	2.03	1	0
Kahler Disease [description not available]	2.03	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.03	1	0
Autoimmune Disease [description not available]	2.04	1	0
Dysmyelopoietic Syndromes [description not available]	2.04	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	2.04	1	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.04	1	0
African Lymphoma [description not available]	2.01	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	2.01	1	0
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	2.01	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	2.01	1	0

bromohydrin pyrophosphate

Description

Cross-References

Synonyms (19)

Roles (1)

Drug Classes (2)

Bioassays (3)

Research

Studies (30)

Market Indicators

Research Demand Index: 16.00

Study Types